1.4 KiB
1.4 KiB
{
"action": "flag_duplicate",
"candidates": [
"glp-1-receptor-agonists-for-obesity-create-a-continuous-treatment-paradox-where-efficacy-drives-demand-and-cost-to-fiscal-unsustainability.md",
"state-medicaid-programs-face-significant-budgetary-pressure-from-glp-1-medications-for-obesity.md",
"glp-1-medication-coverage-decisions-are-increasingly-driven-by-state-budgetary-constraints-rather-than-clinical-efficacy.md"
],
"reasoning": "The new claim 'California Medi-Cal's 2026 GLP-1 obesity coverage elimination demonstrates the continuous-treatment paradox, where drug efficacy drives demand and cost to fiscal unsustainability.' directly supports and provides concrete evidence for the existing claim 'glp-1-receptor-agonists-for-obesity-create-a-continuous-treatment-paradox-where-efficacy-drives-demand-and-cost-to-fiscal-unsustainability.md'. It also provides specific evidence for 'state-medicaid-programs-face-significant-budgetary-pressure-from-glp-1-medications-for-obesity.md' and 'glp-1-medication-coverage-decisions-are-increasingly-driven-by-state-budgetary-constraints-rather-than-clinical-efficacy.md'. The reviewer noted that the new claim 'substantially overlaps' and is 'redundant' with existing claims, particularly the one about the continuous treatment paradox, as it uses the same core evidence (California's cost trajectory and Newsom's justification) to make a very similar argument."
}